MedinCell S.A.
MDCLF · OTC
3/31/2025 | 9/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.23 | -0.03 | 0.09 |
| FCF Yield | 0.00% | 11.71% | -0.18% | -7.36% |
| EV / EBITDA | 0.00 | -28.98 | -19.66 | -65.17 |
| Quality | ||||
| ROIC | 0.00% | -22.51% | -45.26% | -21.77% |
| Gross Margin | 0.00% | 100.00% | 91.26% | 58.55% |
| Cash Conversion Ratio | -1.48 | 0.01 | 1.61 | 0.56 |
| Growth | ||||
| Revenue 3-Year CAGR | 42.88% | 44.09% | 18.63% | 4.22% |
| Free Cash Flow Growth | 0.00% | 6,477.31% | 97.52% | -25.37% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -3.85 | -3.42 | -14.27 |
| Interest Coverage | 0.00 | -4.24 | -2.70 | -4.24 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.40 | 0.00 |
| Cash Conversion Cycle | 0.00 | 27.44 | -224.69 | -35.28 |